


FOSTER PHARMACEUTICALS LIMITED --

**FINANCIAL STATEMENTS FOR THE PERIOD
ENDED**

COMPANY REGISTRATION NUMBER

31 March 2015

716242



FOSTER PHARMACEUTICALS LIMITED --

Balance Sheet

As at 31 March 2015

		Period ended 31 March 2015	Year ended 31 December 2013
	NOTES	£	£
Investments in subsidiary companies		0	0
Debtors			
Amounts falling due after more than one year	1	9,579	9,579
Creditors			
Amounts falling due after more than one year	2	0	0
Total Net Assets		9,579	9,579
Capital and Reserves			
Called up share capital	3	500	500
Share premium account		0	0
Capital reserve		0	0
Revaluation reserve		9,079	9,079
Other reserves		0	0
Profit and loss account		0	0
Total shareholder's funds		9,579	9,579

For the period ending 31 March 2015 the company was entitled to exemption from audit under section 480 of the Companies Act 2006. relating to dormant companies.


Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

By Order of the Board



W. Hall

Director

29 September 2015

FOSTER PHARMACEUTICALS LIMITED --

Notes to the Accounts

	Period ended 31 March 2015	Year ended 31 December 2013
	£	£
1 Debtors amounts falling due after one year		
Amounts owed by group undertakings	<u>9,579</u>	<u>9,579</u>
2 Creditors amounts falling due after one year		
Amounts owing to group undertakings	<u>0</u>	<u>0</u>
3 Called up share capital		
<i>Authorised</i>		
1000 Ordinary shares of £1 each	<u>1,000</u>	<u>1,000</u>
<i>Issued</i>		
500 Ordinary shares of £1 each	<u>500</u>	<u>500</u>
	<u>500</u>	<u>500</u>
4 Ultimate parent undertaking and ultimate controlling party		

On 6 February 2014 the ultimate parent undertaking and controlling party of the Company changed from Franz Haniel & Cie GmbH, a company registered in Germany, to McKesson Corporation, a company registered in North America. This followed completion of the acquisition of more than 75% of Celesio shares by McKesson Deutschland GmbH & Co. KGaA (formerly Dragonfly GmbH & Co. KGaA).